Xueyun Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xueyun Zhang has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Jiming Zhang
Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Department of Infectious Diseases, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University
3 shared publications - Yuxian Huang
Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital Fudan University Shanghai China
3 shared publications Huazhen Zhao
Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital Fudan University Shanghai China
2 shared publicationsJiajia Han
Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital Fudan University Shanghai China
2 shared publications- Jiajia Han
Department of Infectious Diseases Henan Provincial People's Hospital, Zhengzhou University People's Hospital Zhengzhou Henan China
2 shared publications - Jianming Zheng
Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China
2 shared publications
Latest Publications
- 19 March 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (3) , e70871
3D Radiomics Analysis Based on Liver CT Imaging for Predicting Hepatic Encephalopathy in HBV‐ACLF Patients
Hepatic encephalopathy (HE) is an independent risk factor for mortality in patients with hepatitis B virus‐related acute‐on‐chronic liver failure (HBV‐ACLF). We aim to assess the effectiveness of 3D deep learning based on CT imaging in predicting HE in HBV‐ACLF patients. A retrospective study was conducted on 222 HBV‐ACLF patients who underwent CT scans at two medical centers. The cohort from Huashan Hospital, consisting of 146 patients, was randomly divided into a training cohort ( n = 102) and a validation cohort ( n = 44). An external test cohort ( n = 76) was sourced from Shanghai Public Health Clinical Center. We employed two architectures, ResNet50 and DenseNet201, to extract 3D deep learning features related to HE. Classical radiomics features were extracted from liver CT images and modeled using three machine learning algorithms. Clinical features associated with HE were analyzed via multivariate logistic regression. The 3D deep learning model demonstrated strong performance in predicting HE in ACLF patients, particularly the ResNet50 model, which achieved AUC values of 0.844 (95% CI: 0.752–0.936) in the training cohort, 0.833 (95% CI: 0.671–0.996) in the validation cohort, and 0.833 (95% CI: 0.686–0.981) in the test cohort. Classical radiomics also demonstrated predictive potential, where XGBoost outperformed other algorithms. INR and ammonia levels were independently associated with HE. The nomogram model integrating 3D deep learning, radiomics features, and clinical predictors achieved the highest predictive accuracy across all cohorts. 3D deep learning performed excellently in predicting HE in ACLF patients, and its combination with radiomics and clinical features further enhanced predictive performance.
- 19 March 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (3) , e70871
3D Radiomics Analysis Based on Liver CT Imaging for Predicting Hepatic Encephalopathy in HBV‐ACLF Patients
Hepatic encephalopathy (HE) is an independent risk factor for mortality in patients with hepatitis B virus‐related acute‐on‐chronic liver failure (HBV‐ACLF). We aim to assess the effectiveness of 3D deep learning based on CT imaging in predicting HE in HBV‐ACLF patients. A retrospective study was conducted on 222 HBV‐ACLF patients who underwent CT scans at two medical centers. The cohort from Huashan Hospital, consisting of 146 patients, was randomly divided into a training cohort ( n = 102) and a validation cohort ( n = 44). An external test cohort ( n = 76) was sourced from Shanghai Public Health Clinical Center. We employed two architectures, ResNet50 and DenseNet201, to extract 3D deep learning features related to HE. Classical radiomics features were extracted from liver CT images and modeled using three machine learning algorithms. Clinical features associated with HE were analyzed via multivariate logistic regression. The 3D deep learning model demonstrated strong performance in predicting HE in ACLF patients, particularly the ResNet50 model, which achieved AUC values of 0.844 (95% CI: 0.752–0.936) in the training cohort, 0.833 (95% CI: 0.671–0.996) in the validation cohort, and 0.833 (95% CI: 0.686–0.981) in the test cohort. Classical radiomics also demonstrated predictive potential, where XGBoost outperformed other algorithms. INR and ammonia levels were independently associated with HE. The nomogram model integrating 3D deep learning, radiomics features, and clinical predictors achieved the highest predictive accuracy across all cohorts. 3D deep learning performed excellently in predicting HE in ACLF patients, and its combination with radiomics and clinical features further enhanced predictive performance.
- 18 August 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (8) , e70551
Circulating Cell‐Free Mitochondrial DNA as a Prognostic Biomarker in Patients With HBV‐Related Acute‐on‐Chronic Liver Failure
Acute‐on‐chronic liver failure (ACLF), particularly hepatitis B virus‐related ACLF (HBV‐ACLF), is a severe condition with high short‐term mortality. This study aimed to evaluate the prognostic value of circulating cell‐free mitochondrial DNA (cf‐mtDNA) in predicting short‐term mortality in HBV‐ACLF patients. A total of 320 HBV‐ACLF patients were included in the study population, with 192 patients in the derivation cohort and 128 in the validation cohort. Plasma cf‐mtDNA levels were quantified using qPCR. Plasma cf‐mtDNA levels were significantly elevated in HBV‐ACLF patients (3.95 log 10 copies/μL) compared to healthy controls (2.99 log 10 copies/μL) and patients with chronic liver disease (3.03 log 10 copies/μL) ( p < 0.001). Plasma cf‐mtDNA levels progressively increased with disease severity and were associated with multi‐organ failure. Sequential measurements of cf‐mtDNA showed a significant decrease in survivors (4.00 vs. 3.78 log 10 copies/μL, p = 0.019), while non‐survivors maintained persistently elevated levels with minimal change (4.19 vs. 4.15 log 10 copies/μL, p = 0.359). The cut‐off value of 3.9 log 10 copies/μL for cf‐mtDNA effectively stratified patients into high‐ and low‐risk groups, with significantly lower survival rates in the high‐risk group (28‐day: 46.2% vs. 86.0%, p < 0.001; 90‐day: 37.7% vs. 72.1%, p < 0.001). Using cf‐mtDNA in combination with key clinical parameters, we developed a novel prognostic score that exhibited superior predictive accuracy for 28‐ and 90‐day mortality (AUROCs: 0.907 and 0.906, respectively), outperforming established prognostic scores (all p < 0.05). These findings were validated in an independent cohort. Cf‐mtDNA is a superior biomarker for predicting short‐term mortality in HBV‐ACLF. Its association with multi‐organ failure and disease severity highlights the potential utility in early risk assessment and treatment optimization.
- 18 August 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (8) , e70551
Circulating Cell‐Free Mitochondrial DNA as a Prognostic Biomarker in Patients With HBV‐Related Acute‐on‐Chronic Liver Failure
Acute‐on‐chronic liver failure (ACLF), particularly hepatitis B virus‐related ACLF (HBV‐ACLF), is a severe condition with high short‐term mortality. This study aimed to evaluate the prognostic value of circulating cell‐free mitochondrial DNA (cf‐mtDNA) in predicting short‐term mortality in HBV‐ACLF patients. A total of 320 HBV‐ACLF patients were included in the study population, with 192 patients in the derivation cohort and 128 in the validation cohort. Plasma cf‐mtDNA levels were quantified using qPCR. Plasma cf‐mtDNA levels were significantly elevated in HBV‐ACLF patients (3.95 log 10 copies/μL) compared to healthy controls (2.99 log 10 copies/μL) and patients with chronic liver disease (3.03 log 10 copies/μL) ( p < 0.001). Plasma cf‐mtDNA levels progressively increased with disease severity and were associated with multi‐organ failure. Sequential measurements of cf‐mtDNA showed a significant decrease in survivors (4.00 vs. 3.78 log 10 copies/μL, p = 0.019), while non‐survivors maintained persistently elevated levels with minimal change (4.19 vs. 4.15 log 10 copies/μL, p = 0.359). The cut‐off value of 3.9 log 10 copies/μL for cf‐mtDNA effectively stratified patients into high‐ and low‐risk groups, with significantly lower survival rates in the high‐risk group (28‐day: 46.2% vs. 86.0%, p < 0.001; 90‐day: 37.7% vs. 72.1%, p < 0.001). Using cf‐mtDNA in combination with key clinical parameters, we developed a novel prognostic score that exhibited superior predictive accuracy for 28‐ and 90‐day mortality (AUROCs: 0.907 and 0.906, respectively), outperforming established prognostic scores (all p < 0.05). These findings were validated in an independent cohort. Cf‐mtDNA is a superior biomarker for predicting short‐term mortality in HBV‐ACLF. Its association with multi‐organ failure and disease severity highlights the potential utility in early risk assessment and treatment optimization.
- Open Access
- 10 July 2023
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2023, 1-12
Plasma S100A8 and S100A9 Are Strong Prognostic Factors for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure
Objectives. The rapidly evolving organ failure and high short-run mortality of acute-on-chronic liver failure (ACLF) are inseparable from the role of systemic inflammatory response. S100A8 and S100A9 are associated with the excessive cytokine storm and play a decisive part within the process of inflammation. We aimed to clarify the role of them in predicting prognosis of hepatitis B virus-related ACLF (HBV-ACLF). Methods. S100A8 and S100A9 levels were analyzed in plasma of 187 transplant-free HBV-ACLF patients, 28 healthy controls and 40 chronic hepatitis B (CHB) patients. S100A8 and S100A9 mRNAs were checked in liver samples from 32 HBV-ACLF patients with liver transplantation, 19 patients undergoing surgery for hepatic hemangioma and 10 CHB patients with needle biopsy. Results. The plasma levels of the S100A8 and S100A9 were higher in HBV-ACLF patients than in CHB patients (S100A8 : and S100A9 : ) and healthy controls (S100A8 : and S100A9 : ), and similar results were obtained for mRNA expression. Moreover, both proteins were related to ACLF grade, different types of organ failure, and infection, and they correlated with other prognostic scoring systems. S100A8 and S100A9 can dependently predict 28/90-day mortality (28-day: S100A8: hazard ratio (HR): 1.027; 95% confidence interval (CI): 1.007–1.048; , S100A9 : HR: 1.009; 95% CI: 1.001–1.017; , 90-day: S100A8 : HR: 1.023; 95% CI: 1.011–1.035; , S100A9 : HR: 1.008; 95% CI: 1.004–1.012; and ). Among all of the scoring systems, the combined scoring model (S100A8 and S100A9 jointly with the Chronic Liver Failure-Consortium Organ Failure score (CLIF-C OFs)) displayed the highest area under the receiver operating curve (0.923 (95% CI, 0.887–0.961)) in the prediction of 90-day mortality. Conclusions. S100A8 and S100A9 are promising biomarkers for the analysis of risk stratification and prognosis in ACLF patients. In addition, combining them with the CLIF-C OFs may better predict the prognosis of ACLF.
- 10 July 2023
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2023, 1-12
Open AccessPlasma S100A8 and S100A9 Are Strong Prognostic Factors for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure
Objectives. The rapidly evolving organ failure and high short-run mortality of acute-on-chronic liver failure (ACLF) are inseparable from the role of systemic inflammatory response. S100A8 and S100A9 are associated with the excessive cytokine storm and play a decisive part within the process of inflammation. We aimed to clarify the role of them in predicting prognosis of hepatitis B virus-related ACLF (HBV-ACLF). Methods. S100A8 and S100A9 levels were analyzed in plasma of 187 transplant-free HBV-ACLF patients, 28 healthy controls and 40 chronic hepatitis B (CHB) patients. S100A8 and S100A9 mRNAs were checked in liver samples from 32 HBV-ACLF patients with liver transplantation, 19 patients undergoing surgery for hepatic hemangioma and 10 CHB patients with needle biopsy. Results. The plasma levels of the S100A8 and S100A9 were higher in HBV-ACLF patients than in CHB patients (S100A8 : and S100A9 : ) and healthy controls (S100A8 : and S100A9 : ), and similar results were obtained for mRNA expression. Moreover, both proteins were related to ACLF grade, different types of organ failure, and infection, and they correlated with other prognostic scoring systems. S100A8 and S100A9 can dependently predict 28/90-day mortality (28-day: S100A8: hazard ratio (HR): 1.027; 95% confidence interval (CI): 1.007–1.048; , S100A9 : HR: 1.009; 95% CI: 1.001–1.017; , 90-day: S100A8 : HR: 1.023; 95% CI: 1.011–1.035; , S100A9 : HR: 1.008; 95% CI: 1.004–1.012; and ). Among all of the scoring systems, the combined scoring model (S100A8 and S100A9 jointly with the Chronic Liver Failure-Consortium Organ Failure score (CLIF-C OFs)) displayed the highest area under the receiver operating curve (0.923 (95% CI, 0.887–0.961)) in the prediction of 90-day mortality. Conclusions. S100A8 and S100A9 are promising biomarkers for the analysis of risk stratification and prognosis in ACLF patients. In addition, combining them with the CLIF-C OFs may better predict the prognosis of ACLF.
- Open Access
Identification of Estradiol Benzoate as an Inhibitor of HBx Using Inducible Stably Transfected HepG2 Cells Expressing HiBiT Tagged HBx
HBx plays a significant role in the cccDNA epigenetic modification regulating the hepatitis B virus (HBV) life cycle and in hepatocyte proliferation and carcinogenesis. By using the sleeping-beauty transposon system, we constructed a tetracycline-induced HBx-expressing stable cell line, SBHX21. HBx with a HiBiT tag can be quickly detected utilizing a NanoLuc-based HiBiT detection system. By screening a drug library using SBHX21 cells, we identified estradiol benzoate as a novel anti-HBx agent. Estradiol benzoate also markedly reduced the production of HBeAg, HBsAg, HBV pgRNA, and HBV DNA in a dose-dependent manner, suggesting that estradiol benzoate could be an anti-HBV agent. Docking model results revealed that estradiol benzoate binds to HBx at TRP87 and TRP107. Collectively, our results suggest that estradiol benzoate inhibits the HBx protein and HBV transcription and replication, which may serve as a novel anti-HBV molecular compound for investigating new treatment strategies for HBV infection.
Open AccessIdentification of Estradiol Benzoate as an Inhibitor of HBx Using Inducible Stably Transfected HepG2 Cells Expressing HiBiT Tagged HBx
HBx plays a significant role in the cccDNA epigenetic modification regulating the hepatitis B virus (HBV) life cycle and in hepatocyte proliferation and carcinogenesis. By using the sleeping-beauty transposon system, we constructed a tetracycline-induced HBx-expressing stable cell line, SBHX21. HBx with a HiBiT tag can be quickly detected utilizing a NanoLuc-based HiBiT detection system. By screening a drug library using SBHX21 cells, we identified estradiol benzoate as a novel anti-HBx agent. Estradiol benzoate also markedly reduced the production of HBeAg, HBsAg, HBV pgRNA, and HBV DNA in a dose-dependent manner, suggesting that estradiol benzoate could be an anti-HBV agent. Docking model results revealed that estradiol benzoate binds to HBx at TRP87 and TRP107. Collectively, our results suggest that estradiol benzoate inhibits the HBx protein and HBV transcription and replication, which may serve as a novel anti-HBV molecular compound for investigating new treatment strategies for HBV infection.
- 1 September 2012
- Published by Elsevier in Separation and Purification Technology
- Vol. 98, 249-254
Purification of phosphorus by a zero pollution zone melting technique
- 1 September 2012
- Published by Elsevier in Separation and Purification Technology
- Vol. 98, 249-254
Purification of phosphorus by a zero pollution zone melting technique